Medically reviewed by Steffini Stalos, DO Hemophilia disease is a rare inherited bleeding disorder. People with this genetic ...

Treatment involved an antithrombin-based dose regimen targeting antithrombin levels between 15% and 35%, starting at 50 mg ...

The Centers for Disease Control and Prevention (CDC) report that the exact number of people with hemophilia in the United States is unknown, but recent data suggests that as many as 33,000 males ...

This publication examines the clinical and economic impact of hemophilia A, treatment goals, FDA-approved therapies, and managed care factors. People with hemophilia experience lower bone mineral ...

Jonathan James, CEO, Hope Charities, discusses the critical importance of maintaining access to life-saving medications for ...

Due to hemophilia A patients switching to newer treatments, Takeda Pharmaceuticals is discontinuing both Hemofil M and Recombinate globally.

Though research is still ongoing, recent research in gene therapy has led to potentially life-altering treatment for hemophilia B. Other research has improved IX factor products that allow people ...

Hemophilia has loomed large through ... "There's going to be a lot of poor people who can't afford this," McMillan said. Robert Lojewski, a senior vice president and general manager at CSL ...

People with hemophilia have a defect in a gene that regulates production of proteins called clotting factors. It primarily affects men and causes spontaneous and potentially severe bleeding after ...

Columnist Alliah Czarielle urges those with hemophilia to remember the power of movement, even if they sense that activity invites trouble.

Dr. Russell Gollard is the Director of Medical Oncology at OptumCare Cancer Care and a Clinical Associate Professor at the University of Nevada, Las Vegas. He has no relevant commercial financial ...